An earlier Assessment (2001) concluded that intracoronary brachytherapy with ribbons containing gamma or beta radioactive seeds met the Blue Cross and Blue Shield (BCBS) Technology Evaluation Center criteria to manage in-stent restenosis of native coronary vessels. This updated assessment addresses five additional indications for use of intracoronary brachytherapy after a successful percutaneous coronary intervention (PCI), each of which failed to meet the TEC criteria in the previous Assessment. These include:

1. de novo stenosis in native coronary vessels; 2. restenosis of native vessels at an unstented site of prior percutaneous coronary intervention PCI; 3. de novo stenosis in a saphenous vein grafts (SVG); 4. restenosis of a SVG at an unstented site of prior PCI; and 5. in-stent restenosis in an SVG.